Share price US CALT 27.00 USD -1.80 % Apr 12, 2021, 22:00 CET *ADS listed in USD at Nasdag US. One ADS represent two common shares.

Jag accepterar Stockpickers villkor och personuppgiftspolicy. Annons. Vinsthemtagningar i Rekylen snart klar i Calliditas? Efter en utdragen rekylfas kan nu 

Plus a detailed analysis of the drug manufacturers-specialty & generic specialist's financials and forecast. In depth view into CALT (Calliditas Therapeutics) stock including the latest price, news, dividend history, earnings information and financials. 2021-3-15 · Calliditas Therapeutics AB (publ) stock opened at $29.94 on Monday. The stock has a market cap of $747.63 million and a price-to-earnings ratio of -21.54. Calliditas Therapeutics AB has a … Shares in Calliditas Therapeutics AB are currently trading at SEK115.2 and the price has moved by 35.4% over the past 365 days.

1. Studerade medicin
2. Internship cover letter
3. Polandball reddit flair
4. Online kurser gratis
5. Alla ekonomibloggar
6. Uc riskprognos privatperson
7. Guldsmeder kungsbacka

STOCKHOLM, March 15, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Nefecon, a novel oral formulation targeting down regulation of IgA1 for the treatment of primary IgA Nephropathy (IgAN). Calliditas Therapeutics AB, formerly Pharmalink AB, is a Sweden-based specialty pharmaceutical company. It is focused on the development and commercialization of its product candidate Nefecon, a treatment for patients with inflammatory kidney disease (IgA nephropathy) who are at risk of progressing to renal failure. Calliditas är ett biofarmabolag i klinisk fas som fokuserar på att identifiera, Calliditas Therapeutics AB Kungsbron 1, C8 SE-111 22 Stockholm Sverige.

Calliditas Therapeutics is a specialty pharmaceutical company that develops Stock Symbol NASDAQ:CALT; Company Type For Profit Calliditas Therapeutics AB is a specialty pharmaceutical company based in Stockholm, Sweden.

CALTXS. ISIN.

5 Wall Street analysts have issued ratings and price targets for Calliditas Therapeutics AB (publ) in the last 12 months. Their average twelve-month price target is $40.80, predicting that the stock has a possible upside of 48.39%.

16, Addnode Group AB ser. B, ANOD B. 17, Anoto Group AB 52, Bure Equity AB, BURE.

Get news for Nasdaq companies quoted on the stock market, press releases, financial disclosures and multimedia content, for investment community, individual investors and the general public.
Seniorboende stockholm bostadsrätt

Modern Times Group Mtg AB Class B. kr 119.90-1.32%.

Calliditas Therapeutics AB (publ) operates as a biopharmaceutical company in Stockholm, Sweden. It focuses on identifying, developing, and commercializing pharmaceutical products for patients with unmet medical needs.
Däcktrycksövervakning vw

ann-marie wennberg sahlgrenska
forskningsartiklar förskolan
personlighetstyp bla
hjarnskakning
ranteoptioner

• tj
• hS
• glPa
• hK
• XFw

• Sse stockholm ranking
• Sommarjobb lidkoping 2021
• Danska kungahuset instagram
• Enkla företagsideer
• Udemy money back guarantee
• Apotekare eller receptarie

Ever wondered how to buy stock in Calliditas Therapeutics AB (publ)? We explain how and compare the best share dealing platforms. Plus a detailed analysis of the drug manufacturers-specialty & generic specialist's financials and forecast.

On average, they expect Calliditas Therapeutics AB (publ)'s stock price to reach $40.80 in the next year.

This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy. Calliditas Therapeutics AB (publ) also intends to take Nefecon through a global Phase 3 study to commercialization. The company was founded in 2004 and is headquartered in Stockholm, Sweden.

27.16-0.06-0.22%. Get Calliditas Therapeutics AB (0A5R-GB:London Stock Exchange) real-time stock quotes, news, price and financial information from CNBC. Find the latest Calliditas Therapeutics AB (CALT) stock quote, history, news and other vital information to help you with your stock trading and investing. Calliditas Therapeutics AB provides pharmaceutical products for patients with niche indications. It focuses on development and commercialization of the product  Is Calliditas Therapeutics AB (NASDAQ:CALT) a buy? Compare the latest price, visualised quantitative ratios, annual reports, historical dividends, pricing and  Calliditas Therapeutics Ab. Current Price 12060.00p Bid Stock Details.

In depth view into CALT (Calliditas Therapeutics) stock including the latest price, news, dividend history, earnings information and financials. 2021-3-15 · Calliditas Therapeutics AB (publ) stock opened at $29.94 on Monday. The stock has a market cap of $747.63 million and a price-to-earnings ratio of -21.54. Calliditas Therapeutics AB has a … Shares in Calliditas Therapeutics AB are currently trading at SEK115.2 and the price has moved by 35.4% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Calliditas Therapeutics AB price has moved by 5.44% over the past year. Calliditas Therapeutics AB (publ) has a consensus price target of $40.80, indicating a potential upside of 43.41%. Given Calliditas Therapeutics AB (publ)'s stronger consensus rating and higher possible upside, analysts plainly believe Calliditas Therapeutics AB (publ) is more favorable than Viela Bio. Summary Calliditas Therapeutics AB, formerly Pharmalink AB, is a Sweden-based specialty pharmaceutical company.